Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature
Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature
复制标题
多发性非白血病髓样肉瘤患者自体造血细胞移植后的长期缓解及文献综述
DOI：
10.1159/000455998
复制
发表时间：
2017-01-01
影响因子：
2.4
通讯作者：
Xu, Yang
中科院分区：
文献类型：
--
作者：
Liang, Yun;Gao, Jie;Xu, Yang
多发性非白血病性骨髓肉瘤（MS）是一种罕见的MS形式，在诊断时发生在骨髓以外的多个解剖部位，先前没有骨髓肿瘤。多发性非白血病MS的患病率、预后和最佳治疗尚未得到解决。同种异体或自体造血细胞移植（HCT）对非白血病MS的作用也不太明确。我们提出了一个MS的情况下，其特点是全身淋巴结病和多发性积液，据推测有一个非常差的预后。患者接受了急性髓性白血病型诱导化疗和自体外周血干细胞移植治疗，出乎意料的是，她已经保持无病超过6年。我们还回顾了关于这种罕见疾病的文献，发现与总体非白血病MS人群相比，多发性非白血病MS与年龄较小和预后较差相关。我们认为，自体HCT是年轻化疗敏感性疾病患者的有效选择，应在最小残留疾病阴性完全缓解状态下进行。
Multiple nonleukemic myeloid sarcoma (MS) is a rare form of MS that is developed in multiple anatomic sites other than bone marrow at diagnosis, without a preceding myeloid neoplasm. The prevalence, prognosis, and optimal management of multiple nonleukemic MS have not been addressed. The role of allogenic or autologous hematopoietic cell transplantation (HCT) for nonleukemic MS is also less well defined. We present a case of MS characterized by systemic lymphadenopathies and multiple effusions, which presumably had a very poor prognosis. The patient was treated with acute myeloid leukemia-type induction chemotherapy and autologous peripheral blood stem cell transplantation, and, unexpectedly, she has remained disease free for more than 6 years. We also reviewed the literature on this rare disease, and found that multiple nonleukemic MS was associated with younger age and a worse prognosis when compared with the overall nonleukemic MS population. We suggest that autologous HCT represents a valid option for young patients with chemosensitive disease and should be performed at the status of minimal residual disease-negative complete remission.